1.
J Fr Ophtalmol
; 44(3): 441-442, 2021 Mar.
Article
in English
| MEDLINE | ID: covidwho-1078010
Subject(s)
Breast Neoplasms/pathology , COVID-19/epidemiology , Iris Neoplasms/secondary , Iris Neoplasms/therapy , Time-to-Treatment , Adult , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/therapy , Combined Modality Therapy , Female , Humans , Iris Neoplasms/pathology , Pandemics , Quarantine , Radiotherapy/methods , Treatment Outcome , Tumor Burden/drug effects , Tumor Burden/radiation effects , Withholding Treatment
2.
Chem Commun (Camb)
; 57(4): 504-507, 2021 Jan 14.
Article
in English
| MEDLINE | ID: covidwho-983835
ABSTRACT
A novel STING agonist, CDGSF, ipsilaterally modified with phosphorothioate and fluorine, was synthesized. The phosphorothioate in CDGSF might be a site for covalent conjugation. Injection of CDGSF generated an immunogenic ("hot") tumor microenvironment to suppress melanoma, more efficiently than dithio CDG. In particular, immunization with SARS-CoV-2 spike protein using CDGSF as an adjuvant elicited an exceptionally high antibody titer and a robust T cell response, overcoming the drawbacks of aluminum hydroxide. These results highlighted the therapeutic potential of CDGSF for cancer immunotherapy and the adjuvant potential of the STING agonist in the SARS-CoV-2 vaccine for the first time.